Search
Search
About
Log in
Join
Experiences with
Lymphocytic leukemia
Posts
Communities
3,092 public posts
Filter results
BTK Degrader Shows Potential for Treating Refractory CLL and SLL
A novel Bruton's tyrosine kinase (BTK) degrader, NX-2127, has shown potential for treating patients with double- and triple-refractory CLL or SLL who have experienced disease progression while on any covalent or non-covalent BTK inhibitor, as well as a BCL2 inhibitor. NX-2127 a BTK degrader has a novel
A novel Bruton's tyrosine kinase (BTK) degrader, NX-2127, has shown potential for treating patients with double- and triple-refractory CLL or SLL who have experienced disease progression while on any covalent or non-covalent BTK inhibitor, as well as a BCL2 inhibitor. NX-2127 a BTK degrader has a novel
Jm954
Administrator
in
CLL Support
1 year ago
Did you know that...
...the subtype of chronic
lymphocytic
leukemia
with VH gene mutations is equally common in men and women, while chronic
lymphocytic
leukemia
without VH gene mutations is 3 times more common in men? I'm just quoting. Curious fact. What to do.
...the subtype of chronic
lymphocytic
leukemia
with VH gene mutations is equally common in men and women, while chronic
lymphocytic
leukemia
without VH gene mutations is 3 times more common in men? I'm just quoting. Curious fact. What to do.
Yalokin
in
CLL Support
2 years ago
JAK2V617F Allele Burden in Polycythemia Vera: Burden of Proof
Polycythemia vera (PV) is a hematopoietic stem cell (HSC) neoplasm defined by activating somatic mutations in the JAK2 gene and characterized clinically by overproduction of red blood cells, platelets, and neutrophils; significant burden of disease-specific symptoms; high rates of vascular events; and
Polycythemia vera (PV) is a hematopoietic stem cell (HSC) neoplasm defined by activating somatic mutations in the JAK2 gene and characterized clinically by overproduction of red blood cells, platelets, and neutrophils; significant burden of disease-specific symptoms; high rates of vascular events; and
Manouche
in
MPN Voice
1 year ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
CLL Webinar
Hi all Here is the link for today's CLL webinar. This educational webinar will give an overview of how CLL is treated today and the significance of ’hot topics’ and key treatment development advances published and discussed at 2022 international hematology conferences. What is new and what does this
Hi all Here is the link for today's CLL webinar. This educational webinar will give an overview of how CLL is treated today and the significance of ’hot topics’ and key treatment development advances published and discussed at 2022 international hematology conferences. What is new and what does this
Irishcll
in
CLL Support
1 year ago
LLS.ORG (USA) WHAT ARE YOUR TOP PRIORITIES FOR 2023?
Dear Advocate, Whether it’s making sure every patient can afford health insurance that works for them or advancing better treatments, LLS is committed to working tirelessly to advance policies that serve the needs of blood cancer patients and their families. In 2023 we will continue to work closely
Dear Advocate, Whether it’s making sure every patient can afford health insurance that works for them or advancing better treatments, LLS is committed to working tirelessly to advance policies that serve the needs of blood cancer patients and their families. In 2023 we will continue to work closely
lankisterguy
Volunteer
in
CLL Support
1 year ago
Diagnosis: "Favors Essential Thrombocythemia"
So this is good news. Except for one thing. My bmb did show some "mild to moderate reticulin fibrosis. Nevertheless the diagnosis favors the ET. My hematologist says that we will keep a close eye on bloodwork going forward. As I have the Calr 1 mutation and am already on Eliquis, no additional medication
So this is good news. Except for one thing. My bmb did show some "mild to moderate reticulin fibrosis. Nevertheless the diagnosis favors the ET. My hematologist says that we will keep a close eye on bloodwork going forward. As I have the Calr 1 mutation and am already on Eliquis, no additional medication
Mtnlife
in
MPN Voice
1 year ago
Drug interactions/conflicts
Hi everyone I am Coeliac and also have Essential Thrombocythemia for which I take Hydroxycarbamide. Amongst the many side effects from HC my regular blood tests have shown me to be borderline anaemic and my regular GP has monitored this for years - checking kidney & liver function, and also on Folate
Hi everyone I am Coeliac and also have Essential Thrombocythemia for which I take Hydroxycarbamide. Amongst the many side effects from HC my regular blood tests have shown me to be borderline anaemic and my regular GP has monitored this for years - checking kidney & liver function, and also on Folate
quanglewangle
in
MPN Voice
1 year ago
Why do we have mutations?
Why do we all have these bone marrow mutations? It cannot all be due to family DNA bad luck. My haemo told me that he is certain that my mutation is due to exposure to Benzene in petroleum products. In effect I have been poisoned by products which were supposed to be safe. Benzene compounds are still
Why do we all have these bone marrow mutations? It cannot all be due to family DNA bad luck. My haemo told me that he is certain that my mutation is due to exposure to Benzene in petroleum products. In effect I have been poisoned by products which were supposed to be safe. Benzene compounds are still
Andrew8
in
MPN Voice
1 year ago
Autoimmune hemolytic anemia (AIHA), Immune thrombocytopenia (ITP) and other autoimmune complications and extranodal involvement in CLL
It's titled [i]"Unusual complications in the management of chronic
lymphocytic
leukemia
".
It's titled [i]"Unusual complications in the management of chronic
lymphocytic
leukemia
".
CLLerinOz
Administrator
in
CLL Support
2 years ago
Your Role in Managing Your Care
leukemia
(CLL)?
leukemia
(CLL)?
lankisterguy
Volunteer
in
CLL Support
2 years ago
Pirtobrutinib triple trial Cycle 7 update
I'm now finishing up Cycle 8 of: [i]
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic
Leukemia
(CLL) or Richter Transformation (RT) [/i] at M.D. Anderson in Houston, TX.
I'm now finishing up Cycle 8 of: [i]
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic
Leukemia
(CLL) or Richter Transformation (RT) [/i] at M.D. Anderson in Houston, TX.
SeymourB
in
CLL Support
9 months ago
CLL Educational Webinar
This educational webinar will give an overview of how CLL is treated today and the significance of ’hot topics’ and key treatment development advances published and discussed at 2022 international hematology conferences. What is new and what does this mean for patients? We will be joined by: Prof Paolo
This educational webinar will give an overview of how CLL is treated today and the significance of ’hot topics’ and key treatment development advances published and discussed at 2022 international hematology conferences. What is new and what does this mean for patients? We will be joined by: Prof Paolo
Irishcll
in
CLL Support
1 year ago
Ruxolitinib/Pegylated Interferon Alpha 2a Reduces Spleen Length in Myelofibrosis
« Such deep molecular responses, to our knowledge, have never been seen in patients with myelofibrosis before,” Kiladjian noted » »A previously developed mathematical model for predicting long-term responses in patients with PV and ET was found to be applicable to this study and predicted a long-term
« Such deep molecular responses, to our knowledge, have never been seen in patients with myelofibrosis before,” Kiladjian noted » »A previously developed mathematical model for predicting long-term responses in patients with PV and ET was found to be applicable to this study and predicted a long-term
Manouche
in
MPN Voice
1 year ago
Early Intervention for CLL
Testing Early Treatment for Patients with Chronic
Lymphocytic
Leukemia
(CLL) or Small
Lymphocytic
Lymphoma (SLL) https://www.swog.org/patients/trials-open-patients/testing-early-treatment-patients-chronic-
lymphocytic
-
leukemia
-cll-or
Testing Early Treatment for Patients with Chronic
Lymphocytic
Leukemia
(CLL) or Small
Lymphocytic
Lymphoma (SLL) https://www.swog.org/patients/trials-open-patients/testing-early-treatment-patients-chronic-
lymphocytic
-
leukemia
-cll-or
CLLnewbie
in
CLL Support
2 years ago
myelofibrosis
hello anyone with mf,I'm not sure if I should start treatment a lot of people on here are on treatment. my platelets are normal, hb slightly low ,slightly enlarged spleen ,fatigue is main symptom. I'm on watch and wait but should I be on something to stop the mf progressing.
hello anyone with mf,I'm not sure if I should start treatment a lot of people on here are on treatment. my platelets are normal, hb slightly low ,slightly enlarged spleen ,fatigue is main symptom. I'm on watch and wait but should I be on something to stop the mf progressing.
glyndale
in
MPN Voice
1 year ago
Patient Empowerment Network New CLL Content March 2023
Dr. Michael Choi explains CLL patient trial opportunities and provides key questions to ask about clinical trial participation View Now >> https://powerfulpatients.org/2022/12/07/hesitant-to-participate-in-a-cll-clinical-trial-what-you-should-know/ - Developing CLL Research and Treatment News
Dr. Michael Choi explains CLL patient trial opportunities and provides key questions to ask about clinical trial participation View Now >> https://powerfulpatients.org/2022/12/07/hesitant-to-participate-in-a-cll-clinical-trial-what-you-should-know/ - Developing CLL Research and Treatment News
lankisterguy
Volunteer
in
CLL Support
1 year ago
Chronic Lymphocytic Leukemia patient survey points to a need for better patient education
The interim report of an ongoing survey of CLL patients demonstrates that over 60% of respondents were unaware of different CLL risk groups and that about 20% felt they had "[i]not received enough information about CLL to make informed treatment decisions"[/i]. 14% of patients surveyed "[i]were unable
The interim report of an ongoing survey of CLL patients demonstrates that over 60% of respondents were unaware of different CLL risk groups and that about 20% felt they had "[i]not received enough information about CLL to make informed treatment decisions"[/i]. 14% of patients surveyed "[i]were unable
CLLerinOz
Administrator
in
CLL Support
2 years ago
Relapse/Refractory CLL
Hi All, At my last appointment w/CLL specialist, in December, he noted that my CLL appears to be becoming active again and I'll likely need treatment again this year. :( Instead of the usual 6-months, he set our next appointment for 3-months, which is coming up this week. So, of course, I've been
Hi All, At my last appointment w/CLL specialist, in December, he noted that my CLL appears to be becoming active again and I'll likely need treatment again this year. :( Instead of the usual 6-months, he set our next appointment for 3-months, which is coming up this week. So, of course, I've been
TeamDirtyBoots
in
CLL Support
1 year ago
Real-world treatments and thrombotic events in polycythemia vera patients in the USA
»The majority of patients in both risk groups (60% of high-risk and 83% of low-risk) initiated treatment with phlebotomy monotherapy, and during a median follow-up period of 808 days, the vast majority (81% low-risk, 74% high-risk) maintained their original therapy during the follow-up period. Hematocrit
»The majority of patients in both risk groups (60% of high-risk and 83% of low-risk) initiated treatment with phlebotomy monotherapy, and during a median follow-up period of 808 days, the vast majority (81% low-risk, 74% high-risk) maintained their original therapy during the follow-up period. Hematocrit
Manouche
in
MPN Voice
1 year ago
Real world experience with Besremi in ET and PV following exposure to Pegasys.
Abstract Despite widespread use of Pegylated forms of Inteferon in the management of Myeloproliferative Neoplasms (MPN), most clinicians have experience predominantly with peginterferon alfa-2a (Pegasys). Third generation pegylated IFNα, ropeginterferon alfa-2b (ropegIFN; Besremi), was recommended
Abstract Despite widespread use of Pegylated forms of Inteferon in the management of Myeloproliferative Neoplasms (MPN), most clinicians have experience predominantly with peginterferon alfa-2a (Pegasys). Third generation pegylated IFNα, ropeginterferon alfa-2b (ropegIFN; Besremi), was recommended
Manouche
in
MPN Voice
1 year ago
1
...
18
19
20
...
100
Next page
10
20
30
40
50
60
70
80
90
100
Filter results
Clear filters
Posted in
All communities
CLL Support
1942 results
MPN Voice
789 results
Leukaemia Support
168 results
View top 10 communities
Sort by
Most Relevant
Newest